Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2023
Reporting Period: Event date March 27, 2023
The Company entered into a Material Definitive Agreement on March 27, 2023, regarding the licensing of its clinical test drug candidates in India.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. The filing text does not provide clear values for financial metrics such as margins, debt, or liquidity.
Material Changes and Agreement Details
The primary material change is the execution of a License Agreement with Karveer Meditech Private Limited ("Karveer"). Key terms include:
- Licensed Products: NV-CoV-2 and NV-CoV-2-R (Two Clinical Test Drug Candidates).
- Territory: India.
- License Type: Limited, non-transferable, exclusive license for development, commercialization, and sale.
- Clinical Trial Sponsorship: Karveer agreed to sponsor Phase I and Phase II clinical trials.
- Cost Reimbursement: NanoViricides will reimburse Karveer for all direct and indirect clinical trial costs plus a customary fee of 30% of such costs.
- Revenue Share: Karveer shall pay NanoViricides 70% of any invoiced commercial sales to unaffiliated third parties.
- Royalties and Fees: No minimum royalties or license maintenance fees are required.
- Data Rights: NanoViricides retains rights to data generated by Karveer for use in other jurisdictions.
- Term: No set term; continues as long as Karveer uses the Company's proprietary technologies.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses solely on the execution of the agreement and does not provide forward-looking guidance, earnings outlook, or specific management commentary beyond the agreement terms.
Risks and Contingencies: The filing notes that the description of the agreement is not complete and is qualified by reference to the full agreement filed as Exhibit 10.1. Specific provisions of the exhibit were redacted pursuant to Regulation S-K.
Investor Verification Checklist
- Verify the full text of the License Agreement (Exhibit 10.1) to review redacted provisions and specific termination clauses.
- Confirm the financial impact of the 30% fee on clinical trial costs and the reimbursement obligations.
- Monitor the progress of Phase I and Phase II clinical trials sponsored by Karveer in India.
- Assess the commercial viability of NV-CoV-2 and NV-CoV-2-R in the Indian market to evaluate the potential 70% revenue share.